Citation Impact
Citing Papers
Crippling life support for SARS-CoV-2 and other viruses through synthetic lethality
2020 StandoutNobel
COVID-19 infection: Emergence, transmission, and characteristics of human coronaviruses
2020 Standout
Eating habits and lifestyle changes during COVID-19 lockdown: an Italian survey
2020 Standout
The Spring α-Helix Coordinates Multiple Modes of HCV (Hepatitis C Virus) NS3 Helicase Action
2016 StandoutNobel
Sofosbuvir and Ribavirin in HCV Genotypes 2 and 3
2014
Treatment predictors of a sustained virologic response in hepatitis B and C
2008
Refinement of stopping rules during treatment of hepatitis C genotype 1 infection with boceprevir and peginterferon/ribavirin
2012
Therapy of chronic hepatitis C virus infection in the era of direct-acting and host-targeting antiviral agents
2013
Recapitulation of the hepatitis C virus life-cycle in engineered murine cell lines
2013 StandoutNobel
SARS and MERS: recent insights into emerging coronaviruses
2016 Standout
Global virus outbreaks: Interferons as 1st responders
2019
Psychiatric and Substance Use Disorders in Individuals with Hepatitis C
2006
Clinical trial: the efficacy and safety of oral PF‐03491390, a pancaspase inhibitor – a randomized placebo‐controlled study in patients with chronic hepatitis C
2010
Hepatitis C virus genotype 3: a genotype that is not ‘easy-to-treat’
2014
Cost–Effectiveness of Hepatitis C Virus Antiviral Treatment for Injection Drug User Populations
2011
Treatment responses in Asians and Caucasians with chronic hepatitis C infection
2008
Analysis of the complete open reading frame of hepatitis C virus in genotype 2a infection reveals critical sites influencing the response to peginterferon and ribavirin therapy
2011
Lethal Mutagenesis of Hepatitis C Virus Induced by Favipiravir
2016 StandoutNobel
Practice guidelines for the diagnosis and management of nonalcoholic fatty liver disease
2010
Randomized Trial of Peginterferon alfa-2b and Ribavirin for 48 or 72 Weeks in Patients with Hepatitis C Virus Genotype 1 and Slow Virologic Response
2010
Diagnosis, management, and treatment of hepatitis C: An update # † ‡
2008 Standout
Antiviral treatment of hepatitis C
2014
Peginterferon-Alfa2a Plus Ribavirin for 48 Versus 72 Weeks in Patients With Detectable Hepatitis C Virus RNA at Week 4 of Treatment
2006
Interferon-based therapy of hepatitis C
2007
Interferon-based therapy for chronic hepatitis C: current and future perspectives
2008
Treating viral hepatitis C: efficacy, side effects, and complications
2006
Antiviral therapy for chronic hepatitis C: past, present, and future
2006
Pegylated Interferon‐α‐2a plus Ribavirin for Treatment‐Naive Asian Patients with Hepatitis C Virus Genotype 1 Infection: A Multicenter, Randomized Controlled Trial
2008
Importance of IL28B gene polymorphisms in hepatitis C virus genotype 2 and 3 infected patients
2010
Mechanisms of action of ribavirin against distinct viruses
2005
Telaprevir Alone or With Peginterferon and Ribavirin Reduces HCV RNA in Patients With Chronic Genotype 2 but Not Genotype 3 Infections
2011
Pegylated interferon alfa and ribavirin for 14 versus 24 weeks in patients with hepatitis C virus genotype 2 or 3 and rapid virological response
2007
Association of Amino Acid Substitution Pattern in Core Protein of Hepatitis C Virus Genotype 1b High Viral Load and Non-Virological Response to Interferon-Ribavirin Combination Therapy
2005
American Gastroenterological Association Technical Review on the Management of Hepatitis C
2006
Expert opinion on the treatment of patients with chronic hepatitis C
2008
Hepatitis C virus: How genetic variability affects pathobiology of disease
2011
Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance
2009 StandoutNature
A Sustained Virologic Response Is Durable in Patients With Chronic Hepatitis C Treated With Peginterferon Alfa-2a and Ribavirin
2010
Is genotype 3 of the hepatitis C virus the new villain?
2013
The global NAFLD epidemic
2013 Standout
Definition of rapid virologic response with a highly sensitive real-time PCR-based HCV RNA assay in peginterferon alfa-2a plus ribavirin response-guided therapy
2010
The HCV Life Cycle: In vitro Tissue Culture Systems and Therapeutic Targets
2014 Standout
Alcoholic Liver Disease: Pathogenesis and New Therapeutic Targets
2011 Standout
Diagnosis and management of chronic viral hepatitis: Antigens, antibodies and viral genomes
2008
Understanding the hepatitis C virus life cycle paves the way for highly effective therapies
2013 StandoutNobel
Early and Accurate Prediction of Peg-IFNs/Ribavirin Therapy Outcome in the Individual Patient With Chronic Hepatitis C by Modeling the Dynamics of the Infected Cells
2008
A Hepatitis C Virus (HCV) Vaccine Comprising Envelope Glycoproteins gpE1/gpE2 Derived from a Single Isolate Elicits Broad Cross-Genotype Neutralizing Antibodies in Humans
2013 StandoutNobel
Optimal therapy in genotype 1 patients
2009
Rapid virological response is the most important predictor of sustained virological response across genotypes in patients with chronic hepatitis C virus infection
2010
Boceprevir for Untreated Chronic HCV Genotype 1 Infection
2011 Standout
The way forward in HCV treatment — finding the right path
2007 StandoutNobel
Replication of hepatitis C virus
2007 StandoutNobel
Peginterferon alfa and ribavirin for chronic hepatitis C in patients eligible for shortened treatment, re-treatment or in HCV/HIV co-infection: a systematic review and economic evaluation
2011
Flying Under the Radar: The Immunobiology of Hepatitis C
2006 StandoutNobel
Antiviral Combination Therapy for Treatment of Chronic Hepatitis B, Hepatitis C, and Human Immunodeficiency Virus Infection
2008
Internal Initiation Stimulates Production of p8 Minicore, a Member of a Newly Discovered Family of Hepatitis C Virus Core Protein Isoforms
2009 StandoutNobel
The HCV IRES pseudoknot positions the initiation codon on the 40S ribosomal subunit
2010 StandoutNobel
Broadly Neutralizing Immune Responses against Hepatitis C Virus Induced by Vectored Measles Viruses and a Recombinant Envelope Protein Booster
2012 StandoutNobel
Next Generation of Fluorine-Containing Pharmaceuticals, Compounds Currently in Phase II–III Clinical Trials of Major Pharmaceutical Companies: New Structural Trends and Therapeutic Areas
2016 Standout
Efficient Replication of Genotype 3a and 4a Hepatitis C Virus Replicons in Human Hepatoma Cells
2012 StandoutNobel
A Comprehensive Computational Analysis for the Binding Modes of Hepatitis C Virus NS5A Inhibitors: The Question of Symmetry
2016 StandoutNobel
Antisense Gets a Grip on miR-122 in Chimpanzees
2010 StandoutNobel
Hepatitis C Virus NS3 Inhibitors: Current and Future Perspectives
2013
Progress towards a hepatitis C virus vaccine
2013 StandoutNobel
Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of mild chronic hepatitis C: a systematic review and economic evaluation
2007
Development of a multiplex phenotypic cell-based high throughput screening assay to identify novel hepatitis C virus antivirals
2013 StandoutNobel
Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care
2011 Standout
Fast Hepatitis C Virus RNA Elimination and NS5A Redistribution by NS5A Inhibitors Studied by a Multiplex Assay Approach
2015 StandoutNobel
Response of Hepatitis C Virus to Long-Term Passage in the Presence of Alpha Interferon: Multiple Mutations and a Common Phenotype
2013 StandoutNobel
Prevention of hepatitis C virus infection using a broad cross‐neutralizing monoclonal antibody (AR4A) and epigallocatechin gallate
2015 StandoutNobel
EASL Recommendations on Treatment of Hepatitis C 2018
2018 Standout
Natural product and natural product derived drugs in clinical trials
2014 Standout
Insulin sensitisers in the treatment of non-alcoholic fatty liver disease: a systematic review.
2011 StandoutNobel
Interaction of obesity and infections
2015
Increased Replicative Fitness Can Lead to Decreased Drug Sensitivity of Hepatitis C Virus
2014 StandoutNobel
Successful anti-scavenger receptor class B type I (SR-BI) monoclonal antibody therapy in humanized mice after challenge with HCV variants with in vitro resistance to SR-BI-targeting agents
2014 StandoutNobel
2013 StandoutNobel
Towards a small animal model for hepatitis C
2009 StandoutNobel
Turmeric curcumin inhibits entry of all hepatitis C virus genotypes into human liver cells
2013 StandoutNobel
Silymarin/Silybin and Chronic Liver Disease: A Marriage of Many Years
2017 Standout
Is 3 the new 1: perspectives on virology, natural history and treatment for hepatitis C genotype 3
2013
Antiretroviral Use in the CEASE Cohort Study and Implications for Direct-Acting Antiviral Therapy in Human Immunodeficiency Virus/Hepatitis C Virus Coinfection
2016 StandoutNobel
Guidelines for the management of hemophilia
2012 Standout
Barrier-Independent, Fitness-Associated Differences in Sofosbuvir Efficacy against Hepatitis C Virus
2016 StandoutNobel
Role of Scavenger Receptor Class B Type I in Hepatitis C Virus Entry: Kinetics and Molecular Determinants
2009 StandoutNobel
Works of F. Vinelli being referenced
Individualized treatment duration for hepatitis C genotype 1 patients: A randomized controlled trial
2007
Determinants of relapse after a short (12 weeks) course of antiviral therapy and re-treatment efficacy of a prolonged course in patients with chronic hepatitis C virus genotype 2 or 3 infection #
2008
Peginterferon Alfa-2b and Ribavirin for 12 vs. 24 Weeks in HCV Genotype 2 or 3
2005